<DOC>
	<DOCNO>NCT02418819</DOCNO>
	<brief_summary>This study design investigate safety , tolerability pharmacokinetics pharmacodynamic effect PF-06412562 follow multiple dose administration MR tablets subject schizophrenia .</brief_summary>
	<brief_title>A Study To Examine Safety , Pharmacokinetics , And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia</brief_title>
	<detailed_description>B7441007 randomize , double-blind , placebo-controlled , sponsor open , parallel group design , Phase 1b study safety , tolerability , pharmacokinetics , pharmacodynamics 3 dos PF-06412562 ( 3 mg BID , 9 mg BID 45 mg BID ) 15 day approximately 100 psychiatrically stable ( defined inclusion exclusion criterion ) subject schizophrenia background treatment SOC antipsychotic psychotropic medication . All dos administer twice daily , approximately 12 hour dose .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Subjects schizophrenia male female 2 . Evidence stable schizophrenia symptomatology least 3 month ( hospitalization schizophrenia , increase level psychiatric care due worsen symptom schizophrenia , etc ) . 3 . Subjects must ongoing maintenance antipsychotic therapy clozapine ( oral depot ) stable medication treatment regimen least 2 month prior Day 1 , include concomitant psychotropic medication . 1 . History seizure 2 . Pregnant nursing female 3 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time screen time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>